BRAF and melanoma: Recent clinical trials with ICI have shown remarkable improvements in long‐term patient outcomes with a 6.5‐year OS rate of 52% for BRAF‐mutant melanoma; however, treatment was accompanied by high rates of toxicities, whereby grade 3 or 4 toxicities were observed in 53% of patients.5, 50, 51